Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Accumulated Expenses (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Accumulated Expenses for 13 consecutive years, with $14.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 75.82% to $14.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.6 million through Dec 2025, down 75.82% year-over-year, with the annual reading at $14.6 million for FY2025, 75.82% down from the prior year.
  • Accumulated Expenses hit $14.6 million in Q4 2025 for Coherus Oncology, up from $13.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $115.7 million in Q1 2024 to a low of $11.0 million in Q2 2025.
  • Historically, Accumulated Expenses has averaged $39.6 million across 5 years, with a median of $27.0 million in 2021.
  • Biggest five-year swings in Accumulated Expenses: surged 331.77% in 2024 and later tumbled 81.96% in 2025.
  • Year by year, Accumulated Expenses stood at $22.0 million in 2021, then surged by 127.57% to $50.1 million in 2022, then soared by 110.36% to $105.4 million in 2023, then tumbled by 42.79% to $60.3 million in 2024, then tumbled by 75.82% to $14.6 million in 2025.
  • Business Quant data shows Accumulated Expenses for CHRS at $14.6 million in Q4 2025, $13.4 million in Q3 2025, and $11.0 million in Q2 2025.